Drug intelligence / Profile preview

piperacillin + tazobactam (Italmed)

Development stage
Unknown
Lead developer
Italmed
Modality
Small Molecules
Administration
Topical
01

Overview

Gelcide is a locally delivered subgingival antibiotic gel formulation containing a combination of the broad-spectrum ureidopenicillin antibiotic piperacillin and the beta-lactamase inhibitor tazobactam. Developed by Italmed in collaboration with MedTechDental and investigated in clinical trials sponsored by MegaGen Dental Implant Romania, Gelcide is designed as an adjunct to non-surgical mechanical debridement (scaling and root planing) for the treatment of stage III–IV periodontitis and peri-implantitis in adults. The product is supplied as a kit containing a powder of piperacillin and tazobactam and a liquid hydroalcoholic solution, which are mixed immediately before application. Once applied subgingivally into the periodontal pocket, the mixture transitions into a bioadhesive gel that seals the pocket, protecting it from bacterial recolonization and gradually releasing the active antimicrobials over 8 to 10 days to target periodontal pathogens.

Brand names
Gelcide
Other names
piperacillin/tazobactam gelpiperacillin-tazobactam gel
02

Targets

NeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on piperacillin + tazobactam (Italmed).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on piperacillin + tazobactam (Italmed).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call